

## AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-13 (canceled)

Claim 14 (currently amended): A method of preventing or controlling TGF $\beta$ -induced cataract or ~~cataract-like disorders~~ after-cataract formation in the eye of a mammalian subject in need of such prevention or control, which comprises the step of administering to the subject an effective amount of one or more inhibitors of TGF $\beta$ .

Claim 15 (previously presented): The method according to claim 14 wherein the one or more inhibitors of TGF $\beta$  are selected from proteins, glycoproteins and proteoglycans.

Claim 16 (previously presented): The method according to claim 15 wherein the protein inhibitors of TGF $\beta$  are selected from antibodies and peptide growth factors.

Claim 17 (previously presented): The method according to claim 15 wherein the glycoprotein inhibitors of TGF $\beta$  are selected from  $\alpha_2$ -macroglobulin, laminin and collagen.

Claim 18 (previously presented): The method according to claim 15 wherein the proteoglycan inhibitors of TGF $\beta$  are selected from decorin, heparan sulfate proteoglycans and biglycan.

Claim 19 (previously presented): An ophthalmological formulation comprising one or more inhibitors of TGF $\beta$  in an ophthalmologically acceptable carrier but excluding conventional pharmaceutically acceptable carriers.

Claim 20 (previously presented): The ophthalmological formulation according to claim 19 wherein the one or more inhibitors of TGF $\beta$  are selected from proteins, glycoproteins and proteoglycans.

Claim 21 (previously presented): The ophthalmological formulation according to claim 20 wherein the protein inhibitors of TGF $\beta$  are selected from antibodies and peptide growth factors.

Claim 22 (previously presented): The ophthalmological formulation according to claim 20 wherein the glycoprotein inhibitors of TGF $\beta$  are selected from  $\alpha_2$ -macroglobulin, laminin and collagen.

Claim 23 (previously presented): The ophthalmological formulation according to claim 20 wherein the proteoglycan inhibitors of TGF $\beta$  are selected from decorin, heparan sulfate proteoglycans and biglycan.

Claim 24 (currently amended): A method of preventing or controlling after-cataract formation in the eye of a mammalian subject following lens implant surgery, which comprises the step of implanting in the eye of the subject a lens coated with one or more TGF $\beta$  inhibitors.

Claim 25 (previously presented): The method according to claim 24 wherein the one or more inhibitors of TGF $\beta$  are selected from proteins, glycoproteins and proteoglycans.

Claim 26 (previously presented): The method according to claim 25 wherein the protein inhibitors of TGF $\beta$  are selected from antibodies and peptide growth factors.

Claim 27 (previously presented): The method according to claim 25 wherein the glycoprotein inhibitors of TGF $\beta$  are selected from  $\alpha_2$ -macroglobulin, laminin and collagen.

Claim 28 (previously presented): The method according to claim 25 wherein the proteoglycan inhibitors of TGF $\beta$  are selected from decorin, heparan sulfate proteoglycans and biglycan.

Claim 29 (withdrawn): A lens implant comprising a coating, the coating including one or more TGF $\beta$  inhibitors.

Claim 30 (withdrawn): The lens implant according to claim 29 coated with one or more TGF $\beta$  inhibitors selected from proteins, glycoproteins and proteoglycans.

Claim 31 (withdrawn): The lens implant according to claim 30 wherein the protein inhibitors of TGF $\beta$  are selected from antibodies and peptide growth factors.

Claim 32 (withdrawn): The lens implant according to claim 30 wherein the glycoprotein inhibitors of TGF $\beta$  are selected from  $\alpha_2$ -macroglobulin, laminin and collagen.

Claim 33 (withdrawn): The lens implant according to claim 30 wherein the proteoglycan inhibitors of TGF $\beta$  are selected from decorin, heparan sulfate proteoglycans and biglycan.

Claim 34 (currently amended): The method of use of inhibitors of TGF $\beta$  in the manufacture and ophthalmological formulation for preventing or controlling TGF $\beta$ -induced cataract or after-cataract formation in the eye of a mammalian subject in need of such prevention or control.

Claim 35 (previously presented): The method according to claim 34 wherein the inhibitors of TGF $\beta$  are selected from proteins, glycoproteins and proteoglycans.

Claim 36 (previously presented): The method according to claim 35 wherein the protein inhibitors of TGF $\beta$  are selected from antibodies and peptide growth factors.

Claim 37 (previously presented): The method according to claim 35 wherein the glycoprotein inhibitors of TGF $\beta$  are selected from  $\alpha_2$ -macroglobulin, laminin and collagen.

Claim 38 (previously presented): The method according to claim 35 wherein the proteoglycan inhibitors of TGF $\beta$  are selected from decorin, heparan sulfate proteoglycans and biglycan.